Scientific Advisor: James Cloyd, Pharm.D.
Dr. Cloyd is a Morse Alumni Distinguished Teaching Professor, Professor of Neurology and Experimental and Clinical Pharmacology, the Lawrence C. Weaver Endowed Chair in Orphan Drug Development, and Director of the Center for Orphan Drug Research at the University of Minnesota College of Pharmacy. His research focuses on the clinical pharmacology of CNS drugs and includes laboratory investigations of drug solubility, stability, and pharmacology; animal studies of pharmacokinetics and efficacy; and clinical trials interrogating drug safety, bioavailability, pharmacokinetics, pharmacogenomics, drug interaction, and efficacy. He has co-authored three approved orphan drug designation applications: diazepam rectal gel (Diastat®), for which he was a key leader in the successful development of the product; intravenous carbamazepine; and intravenous topiramate. He is actively involved in several international and national organizations including the International Conference on Rare Diseases and Orphan Drugs and the American Epilepsy Society, where he served on the Board of Directors from 2009-2011. He has been a member of several National Institute of Neurological Disorders and Stroke (NINDS) data and safety monitoring boards, has served on the NINDS clinical trials study section, and is a voting member of the FDA Advisory Committee on Pharmaceutical Science and Clinical Pharmacology. He obtained his Pharm.D. degree from the University of Kentucky and completed a fellowship in pharmacokinetics at the University of Washington School of Pharmacy.
Scientific Advisor: Pamela Flood, M.D.
Dr. Flood is Professor of Anesthesiology, Perioperative and Pain Medicine at Stanford University. She has over 25 years of experience in the field of medicine. Dr. Flood graduated from and completed her residency in Anesthesiology at Columbia University College Of Physicians And Surgeons. She is currently doing a Fellowship in Pain Management at Stanford University. Her research seeks to understand the factors that are predictive of the variable expression of acute pain, labor pain, and labor progress. Dr. Flood employs preclinical models of labor and acute pain to test novel treatments that can be rapidly translated to clinical medicine.
Scientific Advisor: R. Edward Hogan, M.D.
Dr. Hogan is Professor of Neurology at Washington University in St. Louis School of Medicine and Director of The Comprehensive Epilepsy Center at Barnes-Jewish Hospital. His research interests include the pharmacology and clinical use of antiepileptic medications, semiology of epileptic seizures, and neuro-imaging changes in patients with epileptic seizures. Dr. Hogan has extensive experience as an investigator in multi-center studies of new medications for patients with refractory epileptic seizures and has participated in studies of pharmacokinetics and clinical effects of antiepileptic medications. Dr. Hogan attended medical school at the University of Missouri, Columbia. His post-graduate training includes an internship at Cleveland Metropolitan General Hospital, neurology residency at Case Western Reserve University, and a fellowship in epilepsy through an exchange curriculum involving Case Western Reserve University and The Royal Melbourne Hospital in Melbourne, Australia. He is board certified in neurology through the American Board of Psychiatry and Neurology and in epilepsy monitoring through the American Board of Clinical Neurophysiology.
Scientific Advisor: Steven Shafer, M.D.
Dr. Shafer is Professor of Anesthesiology, Perioperative and Pain Medicine at Stanford University. His research focuses on the clinical pharmacology of intravenous anesthetics and the development of novel methods of pharmacokinetic and pharmacodynamic analysis. Dr. Shafer is the Editor in Chief of Anesthesia and Analgesia. He is the co-founder of Signature Therapeutics, Inc., a privately held biopharmaceutical company focused on creating best-in-class medicines that address unmet needs in the areas of pain management and anesthesia. Dr. Shafer graduated from Princeton University with an A.B., received his M.D. from Stanford, and completed his anesthesia residency at the University of Pennsylvania.
Scientific Advisor: Thomas Sutula, M.D., Ph.D.
Dr. Sutula serves as a Detling Professor, Chairman of the Department of Neurology, and Director for the Center for Neuroscience at the University of Wisconsin. He has also served as the Director of the Comprehensive Epilepsy Program and Director of Electroencephalography at the University of Wisconsin Hospital. Dr. Sutula’s work in neural plasticity and epilepsy has attracted international attention, and he is regarded as an authority on neural plasticity associated with epilepsy and memory disorders. Dr. Sutula is board certified in internal medicine, neurology, and psychiatry. He is active in professional societies, including the American Academy of Neurology, the Society for Neuroscience, and the American Epilepsy Society, and has served as President of the American Epilepsy Society since 2002. He received an A.B. in Chemistry magna cum laude from Princeton University in 1971, an M.D. from the University of Pennsylvania in 1975, and a Ph.D. in Neuroscience from the University of Virginia Medical School in 1985. He has received numerous academic honors and awards, including Phi Beta Kappa, Sigma Xi, and Alpha Omega Alpha, and the Lennox Award from the American Epilepsy Society for career contributions to epilepsy.
Company Advisor: Alan MacInnes, B.Sc. (Hons)
Mr. MacInnes is currently Entrepreneur in Residence at Biogenerator in St. Louis. He has extensive pharmaceutical industry experience as a research and development scientist and project team leader at Pfizer in the U.K. (1992-2003) and the U.S. (2003-2011). He led projects and laboratories across the drug discovery and development continuum, from new drug target validation to Phase II clinical proof of concept, across multiple cardiovascular, metabolic, endocrine, and inflammatory disease areas. He has participated in the identification of ten drug candidates for human clinical development. In addition, Mr. MacInnes has extensive experience in initiating and leading prominent collaborations with leading academic medical centers and performing due diligence for potential product licensing and strategic alliance opportunities. He received his B.Sc. (Hons) degree in Pharmacology from the Sunderland University School of Pharmacy (Sunderland, U.K.).
Company Advisor: John Talley, Ph.D.
Dr. Talley brings 30 years’ experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor of the blockbuster COX-2 inhibitor celecoxib (Celebrex®) and follow-on coxibs Bextra® and Dynastat®. In addition, Dr. Talley played a major role in the discovery of the HIV protease inhibitors Agenerase®, Lexiva®, and Prezista®. In all, he is a co-inventor of eight drugs that have achieved market approval, with several more still in development. He is a co-founder of Euclises Pharmaceuticals, Inc., an oncology company developing third-generation COX-2 inhibitors, and of SARmont, LLC, a medicinal chemistry and drug design consulting firm. He previously served as Senior Vice President at Ironwood Pharmaceuticals and in various roles at G. D. Searle and Pharmacia. He is a named inventor on more than 200 issued U.S. drug patents and has been honored with the prestigious PhRMA Discoverers Award.